New hope for transplant patients battling dangerous virus
NCT ID NCT06853184
Summary
This study is testing whether adding an intravenous drug called artesunate to standard antiviral medications helps control cytomegalovirus (CMV) infection better in people who have received organ transplants. Researchers will compare the combination treatment against standard treatment alone in 90 adult transplant patients with active CMV infection. The goal is to see if the combination reduces virus levels in the blood more effectively while monitoring safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Alexandra Hospital
RECRUITINGWoolloongabba, Australia
Contact Email: •••••@•••••
-
Westmead Hospital
RECRUITINGWestmead, Australia
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.